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Abstract Suspicion that fructose-containing caloric sweet-
eners (FCCS) may play a causal role in the development of
metabolic diseases has elicited intense basic and clinical re-
search over the past 10 years. Prospective cohort studies con-
verge to indicate that FCCS, and more specifically sugar-
sweetened beverages (SSBs), consumption is associated with
weight gain over time. Intervention studies in which FCCS or
SSB consumption is altered while food intake is otherwise left
ad libitum indicate that increased FCCS generally increases
total energy intake and body weight, while FCCS reduction
decreases body weight gain. Clinical trials assessing the ef-
fects of SSB reduction as a sole intervention however fail to
observe clinically significant weight loss. Many mechanistic
studies indicate that excess FCCS can cause potential adverse
metabolic effects. Whether this is associated with a long-term
risk remains unknown. Scientific evidence that excess FCCS
intake causes more deleterious effects to health than excess of
other macronutrients is presently lacking. However, the large
consumption of FCCS in the population makes it one out of
several targets for the treatment and prevention of metabolic
diseases.
Keywords Sugars . Fructose .Metabolic syndrome . Insulin
resistance . Lipotoxicity . Cardiovascular diseases
Introduction
Free fructose and sucrose are naturally present in fruits, veg-
etables, and honey, and have most likely been part of the
human diet since the beginning of mankind. The level of fruc-
tose consumption remained however very low until the nine-
teenth century, when sugar became widely available at a low
cost due to colonial trade. Of interest, the consumption of
sugar was tightly linked with that of sweetened beverages,
initially tea, coffee, and chocolate in the nineteenth century
and later sodas at the beginning of the twentieth century [1, 2].
The debate about the effects of sugar on health is far from
recent. In 1912, the French physician Paul Carton proposed
[3] that human diseases were mainly related to the consump-
tion of three deadly nutrients: alcohol, meat, and industrial
sugar. In the 1960s, Yudkin proposed that pure, white, and
deadly sugar, more than saturated fat, was instrumental in
causing cardiovascular diseases [4, 5]. The adverse effects of
sugars remained however controversial, and another French
physician, Gerard Debry, concluded after an extensive review
of the literature until 1995 that there was little evidence to
support a harmful effect of sugars [6].
The debate about sugar was relaunched in 2004, when
Bray, Niels, and Popkins suspected a causal relationship be-
tween the increased consumption of high-fructose corn syrup
(HFCS) and the rise in the obesity prevalence in the USA [7].
They proposed that fructose was specifically responsible for
adverse health effects due to its specific metabolism. The ini-
tial whistle blowing incriminating novel industrially produced
sweeteners was, in part, linked with the incorrect assumption
that HFCS contained more fructose than sucrose. The actual
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fructose content of HFCS is somewhere between 42 and 55 %
total sugars and therefore shows little difference with sucrose.
Several clinical studies comparing the effects of HFCS and
sucrose concluded that these two sweeteners have very similar
effects [8–10]. Nonetheless, many strong position statements
were published in the scientific literature and in the lay press
stating that sugar, and more specifically its fructose compo-
nent, is a toxic substance and a major determinant of non-
communicable diseases [11–14].
Since this initial renewed interest in fructose-containing
caloric sweeteners (FCCS), many research studies have been
performed and many articles have been published, but the
controversy continues. Several health organizations however
concluded that consumption of added sugar should be drasti-
cally reduced to less than 5 % total energy (http://www.who.
int/nutrition/sugars_public_consultation/en/, https://www.
gov.uk/government/consultations/consultation-on-draft-sacn-
carbohydrates-and-health-report); these recommendations
appear at odds with reports from European Food Safety
Agency [15] and the Institute of Medicine [16] which both
concluded that scientific evidence was lacking to set up an
upper level for sugar consumption.
In this position paper, we attempt to define what we have
learned during these past 10 years, which questions have been
unequivocally answered, and which novel questions arose. In
this process, we did not perform a critical, systematic review
of the impressive literature on the topic but mainly focused on
relevant meta-analyses and critical, systematic reviews pub-
lished between 2007 and February 2015.
Why Did We Initially Suspect That FCCS Are
Deleterious to Metabolic Health?
A role of FCCS in the pathogenesis of metabolic diseases was
originally supported by
– Animal studies, mainly performed in rodents, but also in
other animal species, including non-human primates,
which indicate that adding fructose or sucrose to the diet
can lead to the development of obesity, insulin resistance,
type 2 diabetes, dyslipidemia, and occasionally high
blood pressure [17, 18]. In most of these studies, high-
sugar-fed animals are used as an experimental model of
obesity or metabolic diseases, and the effects of a high
FCCS intake are not directly compared to other
obesogenic high-fat-based diets which produce similar
long-term metabolic alterations [19, 20]. As such, they
unequivocally demonstrate that sugar can induce overeat-
ing, obesity, and metabolic diseases in spontaneously
feeding animals, but come short of demonstrating that this
effect is exclusively related to FCCS.
– A small number of human studies showing that a high-
fructose diet was occasionally associated with the devel-
opment of dyslipidemia [21].
– Epidemiological data showing associations between
FCCS intake and body weight or prevalence/incidence
of metabolic diseases [7, 22–27].
– Allegations that fructose may be obesogenic because of
its propension to stimulate de novo lipogenesis [23–27]
or may elicit inadequate suppression of food intake be-
cause it does not increase the secretion of insulin and gut
satietogenic hormones [28, 29].
What Has Been Learned Over the Past 10 Years?
Far too many original articles and reviews were published in
the scientific literature during this period to review each one in
detail here. Evaluating the impact of this large amount of
studies can however be facilitated by several recent meta-
analyses and critical, systematic reviews that can be grossly
classified into (a) epidemiological studies, (b) clinical inter-
vention studies, and (c) controlled mechanistic studies. The
major meta-analyses published between 2007 and February
2015 [30–38, 39•, 40–42, 43••, 44, 45, 46••, 47, 48••, 49••,
50–52] are listed in Table 1, together with the type of studies
included in the meta-analysis, its major results, and their au-
thors’ main conclusions.
Epidemiological studies are based on analysis of prospec-
tive data available from large cohort of subjects with multiple
dietary evaluations over time and several years of follow-up
on body weight or incidence of metabolic diseases. Such stud-
ies allow identifying statistical associations between dietary
intake at initial assessment or dietary changes observed be-
tween two dietary assessments and subsequent health status.
As such, they are highly valuable to assess the plausibility that
FCCS may be associated with metabolic diseases in real-life
situations [53]. They however do not allow identifying causal
relationship between FCCS and health due to the many pos-
sible confounders [54].
Epidemiological prospective studies show a strong associ-
ation between FCCS intake and body weight gain [40, 55,
56••]. Most studies specifically addressed the effects of
sugar-sweetened beverage (SSB) consumption, however,
and the association between consumption of sugar in solid
foods and obesity is relatively understudied. The results indi-
cate that SSB consumption is strongly associated with higher
total energy intakes [57], and that either SSB, total fructose, or
total FCCS consumption is strongly associated with body
weight gain over time. They however also indicate that other
dietary food components, mainly fried potatoes, red meat, and
processed meat, are also involved in body weight gain [56••].
Furthermore, FCCS consumption is also associated with the
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incidence of dyslipidemia, insulin resistance, and type 2 dia-
betes [58], with incidence or risk factors for cardiovascular
diseases [59–62], with cardiovascular mortality [63•], with
chronic kidney diseases [39•], and with hyperuricemia and
gout [64]. The strength of these associations is generally re-
duced when data are adjusted for body weight, suggesting that
they are, at least in part, secondary to increased body fat mass.
What can be concluded at this stage? The epidemiological
data available so far are quite consistent in pointing toward a
positive association between FCCS consumption and the de-
velopment of obesity. The association is particularly robust for
SSB. These studies further indicate that the association be-
tween SSB consumption and body weight is largely due to
SSB being associated with increased total energy intake
[31, 48••].
Clinical intervention studies on FCCS regroup various
clinical trials aimed at assessing the global effects of changes
in FCCS consumption on pre-defined endpoints in specific
subsets of the population. The intervention here is focused
on FCCS consumption alone (e.g., replacing SSB with water
or artificially sweetened beverages, or adding one or several
servings of SSB per day), while otherwise leaving spontane-
ous food and beverage intake and physical activity uncon-
trolled. Intervention clinical trials answer one specific ques-
tion, that is: will a specified intervention (e.g., reduction of
sugar intake or of SSB intake) be effective in reaching a spec-
ified endpoint (e.g., body weight loss or decreased blood tri-
glyceride concentrations)? As such, they are valuable to eval-
uate whether it may be worth to introduce the intervention into
clinical practice or into public health initiatives. Identification
of underlying mechanism may however be limited because
more than one mechanism may account for variations of the
main outcome. For instance, an intervention trial showing a
beneficial effect of reducing FCCS intake may indicate that
FCCS is specifically obesogenic; the same result may howev-
er also be explained to a reduction in total energy intake
(which suggests that reduction of energy intake from other
nutrients may have had the same effect). Conversely, if the
same intervention trial fails to observe beneficial effects of
FCCS reduction, this may reflect that FCCS do not exert spe-
cific adverse effects; alternatively, this may also be explained
by the absence of compliance (i.e., the participants failing to
comply with the dietary instructions) or by a compensation of
FCCS energy by an increased consumption of other foods.
Many clinical intervention studies have assessed the effects
of reducing or increasing SSB intake in adults and children.
These studies have been further analyzed in very complete
meta-analyses [31, 48••]. Increased consumption of SSB has
been shown to result in significant weight gain compared to
control in both adults and children, and this effect has been
attributed essentially to an increased total energy intake.
Changes in body weight observed in some of these studies
were however much lower than what would have beenTa
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expected from cumulated total energy from SSB [65••, 66••,
67, 68]. Reduction of SSB consumption was generally asso-
ciated with significant weight loss and reduced total energy
intake. Here again, in many trials, weight loss was far less than
what would have been expected based on cumulated SSB
energy deficit, suggesting either low compliance to SSB re-
striction or compensatory increase in total energy intake. Re-
ducing SSB intake was however inconsistently efficient in
children, most likely due to low compliance in this class of
age [31, 48••].
What have we learned from intervention trials? First,
many trials have assessed the effects of adding sugar to
the diet. Quite expectedly, increasing sugar consumption
was associated with some weight gain. The effects of
increasing sugar consumption was not compared to
those of increasing starch or fat consumption, and
hence, these studies fall short of demonstrating that
weight gain is specifically related to sugar. Second,
most studies showed a significant reduction of body
weight when SSB consumption was reduced, which cer-
tainly indicates that the intervention significantly de-
creased total energy intake. Although the body weights
reported in the intervention and control arms were sta-
tistically significant, the actual effect on adiposity was
often very low: in one study, BMI increased from 30.4
to 30.5 kg/m2 in obese adolescent who replaced SSBs
with water and from 30.1 to 30.6 kg/m2 in the control
group [66••]; in another study, body weight non-
significantly increased by 1.3 % in adolescent receiving
SSBs for 6 months, compared to 0.2 and 0.6 % in those
receiving artificially sweetened sodas or water, respec-
tively [69•]. This casts serious doubt on the clinical
efficacy of a reduction of SSB consumption alone.
Controlled mechanistic studies consist of short-term in-
tervention studies in selected groups of individuals, most
often healthy subjects, overweight and obese subjects, or
subjects with type 2 diabetes. The experimental protocols
compare an intervention arm with high FCCS diet to con-
trol arms, which can be either a low FCCS weight-
maintenance diet or isocaloric high-glucose/high-starch/
high-fat diets. These studies specifically address what
might be the consequences of a high FCCS and attempt
to identify potential mechanisms underlying the effects of
excess FCCS. Given their strictly controlled conditions,
each mechanistic study aims at answering a specific ques-
tion (e.g., what are the effects of isocaloric amounts of
sucrose vs. HFCS on blood lipids? Is fructose more
lipogenic than isocaloric amount of glucose? Can excess
fructose impair insulin sensitivity?). Results from mecha-
nistic studies merely assess whether a specific role of
FCCS is plausible as a working hypothesis. They however
cannot assess whether such effects are relevant to the gen-
eral population in free-living conditions.
Total energy intake is an important confounding fac-
tor in these studies. Studies having compared excess
energy intake from FCCS to weight-maintenance, low-
FCCS diets consistently demonstrate that excess FCCS
energy consumption can, within a few days to a few
weeks, increase body weight and body fat stores [70],
enhance hepatic glucose production [71], impair hepatic
suppression of glucose production by insulin [71–73],
increase fasting and postprandial blood triglyceride con-
centration [29, 70, 74, 75], increase intrahepatic fat con-
centration [76•], and cause a rise in blood uric acid
concentrations [70, 77]. Two studies suggested that ex-
cess fructose may increase visceral fat mass while ex-
cess glucose would increase mainly subcutaneous fat
[70]. In one of these studies [70], fructose-induced in-
crease in visceral fat was observed only in males, but
not in females. Altogether, these mechanistic studies un-
fortunately cannot sort out the relative roles of FCCS
and energy intakes. In addition, many of these studies
assessed the effects of pure fructose rather than sucrose
or HFCS, and many of them used levels of daily FCCS
intake well above consumption observed in the general
population.
Hypercaloric FCCS diets consistently caused an in-
crease in blood triglyceride and uric acid concentrations,
while hypercaloric high-glucose or high-fat diets did
not. One meta-analysis concluded that high-fructose in-
take was associated with an increased blood triglyceride
only when associated with excess energy intake, but had
no effects when part of a weight-maintenance diet [34].
In contrast, another study concluded that dietary sugars
influence blood lipids independently of body weight
[49••]. One meta-analysis specifically addressed the ef-
fects of sugar on blood cholesterol and reported that
adverse effects of sugars were observed for doses higher
than 100 g/day [37].
Many narrative reviews and position papers propose
that insulin resistance is a well-recognized effect of di-
etary fructose [78–80]. Moderate increases in fasting
hepatic glucose production are indeed observed within
a few days on a high-fructose diet but are not associat-
ed with clinically relevant increases in blood glucose.
Surprisingly, all studies having actually assessed muscle
insulin sensitivity by hyperinsulinemic-euglycemic
clamps failed to report any muscle insulin resistance in
healthy individuals after 1–4 weeks on a high-fructose
diet [71–73, 81] or in subjects with type 2 diabetes after
3 months [82]. This strongly suggests that fructose per
se, independently of long-term weight changes, does not
impair insulin’s actions in muscle. Interestingly, one
study observed a significant muscle insulin resistance
in middle-aged, overweight offspring of type 2 diabetes
subjects after 6 days on a high-fructose diet [83], while
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another similar study, performed in young, non-
overweight offspring of type 2 diabetes, failed to docu-
ment any changes [81]. This raises the possibility that
fructose’s effects may be modulated by both genetic
background and additional factors such as age or body
fat mass.
Whether FCCS are responsible for an excess food
intake through specific effects involving food intake
control has been the focus of active research and will
not be reviewed comprehensively here. It has been pro-
posed that fructose fails to inhibit the release of the
orexigenic gut hormone ghrelin and increases the release
of satiating gut hormones such as GLP-1 and PYY to a
lesser extent than glucose or starch [29]. This concept
has however been challenged by a recent study showing
that fructose had substantial effects on these gut hor-
mones in normal-weight adolescent. The same study
however reported an impaired suppression of acyl-ghrel-
in, the active form of ghrelin, in obese, insulin-resistant
adolescent [84]. Furthermore, the hypothesis that fruc-
tose may exert less suppression of food intake than
glucose or complex carbohydrate is based on indirect
markers of food intake control, which relates essentially
to the so-called homeostatic systems of food intake reg-
ulation, located in the brain stem and hypothalamus.
Studies with direct measures of food intake and/or sati-
ety feeling failed to document any difference between
fructose and other caloric sweeteners in humans [28, 85,
86]. Food intake regulation results from complex inter-
actions between metabolic, hormonal, and neurologic
signals [87]. There is growing evidence that the hedonic
system of food intake, located in neocortical structures,
and which is involved in food preferences and palatabil-
ity, plays a prominent role in food intake control [88]. It
has further been suggested, based on the fact that oral
sugar ingestion stimulates dopaminergic neurons of the
reward system of the brain stem, hypothalamus, and
cortex, that this may confer to FCCS potentially addic-
tive potential, at least in animals [89–92] and possibly
in humans as well [93]. These are early hypotheses,
which still need more studies to be fully evaluated.
The concept of sugar addiction is highly debated but
suffers from lack of clear diagnosis criteria. Finally,
there is to date no scientific evidence that in humans,
sugars stimulate these neurological pathways to a larger
extent than other food substances with similar palatable
properties.
The effect of intravenous fructose administration on
uric acid production and to cause hyperuricemia has
been long known [94]. Interesting novel observations
have recently been made to link FCCS-induced uric
acid production to metabolic and cardiovascular dis-
eases. According to these novel hypotheses, uric acid
may act as a mediator to induce endothelial cell dys-
function, thus preventing insulin-induced muscle vasodi-
lation. This effect of uric acid has been postulated to
contribute to fructose-induced insulin resistance and
high blood pressure [95]. One isolated clinical study
has supported this hypothesis by showing that a short-
term hypercaloric high-fructose diet increased blood
pressure and that this effect was prevented by adminis-
tration of the uric acid synthesis inhibitor allopurinol
[77]. This observation must however be tempered by
the fact that several other studies failed to observe a
significant effect of a high-fructose diet on blood pres-
sure [45]. Besides vascular effects, uric acid has also
been proposed to enhance lipogenesis and thus to con-
tribute to dyslipidemia and hepatic steatosis [96, 97,
98••]. These novel hypotheses clearly require to be fur-
ther evaluated, and more human studies are needed to
assess their clinical relevance.
What clinically relevant information do these mecha-
nistic studies offer? There is robust evidence that a
high-fructose diet can increase blood triglycerides (TG)
within a few days, enhance IHCL storage, and increase
endogenous glucose production. These changes are
highly significant, yet of small magnitudes, and blood
triglyceride and glucose concentration, as well as
intrahepatic fat content, remain generally within the nor-
mal range. They may of course be early markers of
insulin resistance and progress with time to the devel-
opment of metabolic diseases. There is however an al-
ternative explanation which has been widely disregarded
until now, i.e., that these changes may reflect mere ad-
aptation to a high-fructose diet.
Unlike fructose, glucose and fatty acids are key en-
ergy substrates for animals, and most cells of the human
organism synthesize the enzymes required for glycoly-
sis, beta-oxidation, and degradation of glucose- or fat-
derived acetyl-CoA in the Krebs cycle, coupled to ATP
synthesis in the respiratory chain. In contrast, fructose
cannot be used as such by most cells and requires to be
first pre-processed into glucose, lactate, or fatty acids
[99] . Spec i f ic f ruc tose-metabol iz ing enzymes ,
fructokinase, aldolase B, and triokinase, are present
mainly not only in the liver but also in enterocytes
and tubular kidney cells where this pre-processing oc-
curs (Fig. 1). In the liver, fructolysis, unlike glycolysis,
is neither regulated by insulin nor inhibited by high
concentrations of ATP or citrate. Hepatic production of
glucose, lactate, and fatty acids is therefore mainly de-
pendant on the amount of fructose ingested with a meal
or a drink. The first adaptation that may occur as a
result of fructose ingestion is an increase in hepatic
glucose production [71–73, 100]. As fructose is initially
converted to lactate and glucose in the liver, the
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resulting increased blood lactate and the modest increase
in hepatic glucose production observed in healthy sub-
jects consuming a high-fructose diet do not come as a
real surprise. The second adaption consists in the well-
characterized increase in plasma lipids. However, the
metabolic pathways involved markedly differ from those
resulting from dietary fat ingestion: fructose conversion
into fat occurs essentially in the liver where fructose-
derived fat is either temporarily stored as intrahepatic
fat and/or secreted into the blood as VLDL triglyceride.
In contrast, dietary fats absorbed from the gut are re-
leased as chylomicrons in the lymph, thus avoiding
first-pass hepatic metabolism to be directly stored in
peripheral adipocytes. This difference in the interorgan
trafficking involved in the handling and storage of these
two lipid sources most likely accounts for increased
blood triglyceride concentrations in high-fructose-fed
subjects, since chylomicrons-TG have a half-life in cir-
culation considerably faster than VLDL (Fig. 2).
Whether these alterations of glucose and lipid metabolism
following fructose ingestion are mere adaptations to a tran-
sient change in diet or will in the long term be causally asso-
ciated with adverse vascular effects remains unknown. If that
was the case, it would be important to gather further clinical
observation in order to determine whether such deleterious
effects of FCCS are restricted to the subgroup of subjects at
increased risk due to their genetic background or to specific
patterns of FCCS consumption.
Conclusions
Scientific data regarding the effects of fructose-containing ca-
loric sweeteners presently indicate clearly that
1. Sugar consumption has reached record values in man’s
history during the second half of the twentieth century
Fig. 1 Unlike glucose, which can be used as an energy substrate by all
human cells, fructose cannot be directly metabolized by most cells due to
a much lower affinity of hexokinases for fructose than for glucose.
Instead, fructose is first metabolized in a limited number of organs
(liver, small intestinal mucosa, kidney). In these organs, it is
metabolized to trioses-phosphate (di-hydroxyacetone-phosphate and
glyceraldehyde-3-phosphate) by a set of specific enzymes: fructokinase
(ketohexokinase), aldolase B, and triokinase. Trioses-phosphate can sub-
sequently be further converted into ubiquitous energy substrates: lactate,
glucose, and fatty acids (palmitate, oleate, stearate, …)
Fig. 2 Pathways used for lipid storage from dietary fructose and dietary
fat. Fructose (a) is essentially extracted and metabolized in the liver,
where part of it can be converted into lactate, glucose, fatty acids, and
triglycerides. Newly synthesized glycogen can be temporarily stored as
hepatic glycogen, but its major portion is slowly released into the
systemic circulation as glucose. Hepatic fructose handling differs from
glucose (whether ingested as free glucose, sucrose, or starch; b), which is
only partially extracted by the liver to replenish glycogen stores. Its
largest portion however reaches the systemic circulation, elicits an
increase in blood glucose and insulin concentration, and is metabolized
in insulin-sensitive tissues (muscle, adipose tissue) within a few hours.
After fructose ingestion, new fat synthesized de novo in the liver can be
temporarily stored within the hepatocytes and/or be secreted with VLDL
to be secondarily deposited in adipose tissue (a). In contrast, ingested fat
is mainly absorbed as chylomicrons which circulates in the lymph, thus
bypassing the liver; chylomicrons-TG will then join the systemic circu-
lation and be deposited in adipose tissue (b)
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and the beginning of the twenty-first century and repre-
sents on average close to 20 % total energy intake at the
population level in developed countries.
2. Sugar consumption is consistently associated with in-
creased energy intake and with the development of obe-
sity and metabolic diseases in epidemiological studies.
3. Fructose can cause weight gain when present in a high-
energy diet providing more calories than required for
weight maintenance. There is however no evidence that
similar effects would not be observed when replacing
sugar with glucose, starch, or lipids.
4. A high-fructose diet can increase blood triglyceride, alter
hepatic glucose output, and increase uric acid concentra-
tions. Whether these effects would increase the risk of
metabolic or cardiovascular disease independently of an
increase in body fat mass remains speculative.
Between Science and Common Sense:
Which Practical Steps May Be Considered?
The scientific data reported in the literature appears somewhat
conflicting at first sight. On one hand, there is no strong evi-
dence that, at similar intake levels, sugar exerts worse delete-
rious effects than other energy substrates. Whether sugar
would specifically impair food intake control, or cause tissue
lipotoxicity, remains open questions, but levels of evidence
are presently too low to lead to specific recommendations.
On the other hand, a huge proportion of the population of an
ever-increasing number of countries is overweight. As a nu-
trient accounting to 15–20 % total energy, sugar is certainly
contributing to this global excess energy intake [101–103].
Furthermore, many sugary products have a low content of
essential nutrients and hence low nutritional quality, which
makes them a potential target for energy reduction. This is
particularly true of SSBs. There is no strong evidence that
energy consumed with beverages is more obesogenic than
energy consumed with solid foods and no plausible mecha-
nism to account for such an effect. SSB may nonetheless be
easily overconsumed, possibly because beverage intake is
stimulated by thirst stimuli, such as blood hyperosmolarity
and sodium levels in the distal renal tubules, irrespective of
energy balance. As such, SSB reduction is certainly a prime
target for the prevention of metabolic disorders, assuming that
such decrease will not be compensated by the increase in
caloric intake from solid food.
However, if sugars contribute to excess energy intake, there
is also compelling evidence that sugar-devoid foods, such as
potato chips and meat, are also involved [56••]. Furthermore,
interventions focused solely on SSB or sugar intake have
failed to achieve clinically relevant weight reduction. The ex-
cess body weight of the US population corresponds to a ca.
350–500 kcal/day excess energy intake on average [104]. In
order to revert obesity, energy intake should be reduced by the
same amount; in order to reach this target by specifically de-
creasing sugar intake, added sugar consumption should be
reduced to close to zero, which may be unrealistic in the near
future. Reduction of SSBs, and reformulation of sugar-rich
industrial foods, may certainly contribute to reduced total sug-
ar and energy intake, but it appears obvious that the consump-
tion of other energy-dense foods and/or multifactorial inter-
ventions including consumer education, diet, and physical ac-
tivity will be needed to achieve these goals.
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